In 2007, Marcelo Baru co-funded Nanowattics SRL, Uruguay to design analog custom ICs for safety-critical applications, in particular for implantable devices. The company later expanded to embedded firmware and system design, and around 2014 it obtained an ANII (government agency) grant to develop a bench-top electrical stimulator to run a human pilot study for Diabetic Peripheral Neuropathy (DPN) chronic pain mitigation.

In 2015, a study with 8 patients was conducted at the Diabetic Clinic, Hospital de Clínicas, Montevideo, using a burst-type waveform and a two-electrode TENS patch over the superficial peroneal nerve. The results showed significant improvements: the VAS in the therapy group decreased from 5.33 to 1.91, while the control group saw a reduction from 5.08 to 2.75.

Plans were made to expand the study to 60 patients. However, Nanowattics was integrated into the design center of Allegro Microsystems, U.S.A. in Uruguay in 2016 before the study could proceed.

This previous work laid the groundwork for the EvokedRx™ technology. The burst-type waveform utilized in the human pilot study evolved into the proprietary Duplet Cathodes Therapy (DCT™), and the recent research about Pacinian corpuscles involvement in pain mitigation and their deterioration in diabetes guided us to move from the lower leg to an auricular stimulation approach as we are currently pursuing. Building on these achievements, EvokedRx is well-positioned to deliver innovative solutions in the future.